Difunctionalization of bicyclo[1.1.0]butanes enabled by merging C−C cleavage and ruthenium-catalysed remote C−H activation

In the quest of ‘escaping from flatland’^{1,2,3,4,5,6,7,8}, highly functionalized cyclobutanes with unique puckered linear geometry have received increasing attention in medicinal chemistry. The fraction of sp³-hybridized carbon atoms (Fsp³) was identified as a key descriptor of drug likeness, and the increased Fsp³ in cyclobutanes renders them as a privileged motif for isosteres in drug design⁹. The incorporation of cyclobutane scaffolds often enhances the physicochemical and pharmacokinetic properties of drug molecules. In contrast to usually flat arene rings, polysubstituted cyclobutanes with high Fsp³ can provide, among others, improved solubility due to their nonplanar substituent vectors. Indeed, several pharmaceuticals featuring 1,3-bifunctional cyclobutanes have been clinically tested, such as PF-03654746 (ref. ¹⁰), NVP-ADW 742 (ref. ¹¹), NK1 selective antagonists¹² and Linsitinib¹³, translating into a strong need for innovative cyclobutane syntheses (Fig. 1a). However, in contrast to rather well-established bifunctionalization of bicyclo[1.1.0]pentanes (BCPs)^{14,15,16,17,18} and ring expansions of bicyclo[1.1.0]butanes (BCBs)^{19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41} (Fig. 1b), strategies to access structurally complex cyclobutanes are, unfortunately, scarce. Thus far, these syntheses are limited to radical or nucleophilic additions to BCBs, typically resulting in mono- or disubstituted cyclobutanes^{42,43,44,45,46,47,48,49}, with only few examples for densely substituted cyclobutanes^{50,51,52,53,54}. Furthermore, the aforementioned transformations are largely limited to rather harsh conditions and elements of prefunctionalization on the coupling partner, while the merger of C–C activations^{55,56,57,58,59,60} of BCBs with remote C–H activation⁶¹ has thus far proven elusive. To address these current topical needs, we have now developed the merger of BCBs C–C functionalization with remote C–H functionalization^{62,63,64,65,66,67,68,69,70,71,72,73} by a single, yet powerful, ruthenium(II) catalyst. Salient features of our findings include (1) versatile 1,3-difunctionalization of BCBs for tri- and tetrasubstituted Fsp³-rich cyclobutanes; (2) a single ruthenium complex for a multi-catalysis manifold including an efficient ruthenacycle-mediated halogen-atom transfer (Ru-XAT) process, C–C scission and meta-C–H functionalization; (3) exceedingly mild reaction conditions and (4) outstanding chemo- and site selectivities (Fig. 1c).

a, Selected drug molecules containing 1,3-difunctionalized cyclobutane skeleton. b, Current strategies^{50,51,52,53,54} for the synthesis of highly functionalized cyclobutanes via strain release. c, Our hypothesis on the 1,3-difunctionalization of BCBs by remote C−H activation to access valuable 1,1,3-trisubstituted and 1,1,3,3-tetrasubstituted cyclobutanes via a Ru-XAT process. Ar, aryl.; Het, heteroarenes.

Full size image

Optimization studies

We initiated our studies on BCBs 1,3-difunctionalization through remote C–H activation, with benzyl-bicyclo[1.1.0]butane-1-carboxylate (1a), 2-phenylpyridine (2a) and ethyl-2-bromo-2,2-difluoroacetate (3a) as the model substrates (Table 1). We were pleased to find that the desired product 4 was efficiently obtained in 75% isolated yield with Ru(O₂CMes)₂(p-cymene) as the catalyst and P(4-CF₃C₆H₄)₃ (Table 1, entry 1). Next, a series of phosphines, as well as alternative ligands such as bipyridine (bpy) and N-heterocyclic carbene (NHC), were tested, and P(4-CF₃C₆H₄)₃ was found to be superior (Table 1, entries 2 and 3). Ru(OAc)₂(p-cymene) gave the desired product 4 with 52% yield, while [RuCl₂(p-cymene)]₂ was ineffective (Table 1, entry 4), highlighting the importance of carboxylate assistance in the C–H ruthenation⁷⁴. [Ru(^tBuCN)₅(H₂O)](BF₄)₂⁷⁵ as a precatalyst gave inferior results (Table 1, entry 5). Control experiments revealed the crucial role of the ruthenium catalyst and the phosphine ligand for the BCBs C–C cleavage difunctionalization (Table 1, entry 6).

With the optimized reaction conditions in hand, we subsequently evaluated the viable substrate scope for the bifunctionalization of BCBs 1 with differently substituted heteroarenes 2 (Fig. 2). Arenes with distinct electronic features and substituents, such as fluorine, thioether, bromine, ester and keto groups, were fully tolerated by the versatile catalyst (5–29). Transformable pyrazoles, ketimine and oxazolines could be employed to guarantee meta-selectivity (17–24, 30). Drug-relevant motifs, such as diazepam, purines and nucleoside proved to be viable for the ruthenium-catalysed BCBs difunctionalization (26–29).

Reaction conditions: 1 (0.3 mmol), 2 (3.0 equiv.), 3 (3.0 equiv.), [Ru(O₂CMes)₂(p-cymene)] (10 mol%), P(4-CF₃C₆H₄)₃ (10 mol%), Na₂CO₃ (2.0 equiv.), 1,4-dioxane (2.0 ml), 65 °C, 24–48 h. All yields are isolated yields. The ratios of the diastereomers (cis and trans) were determined by ¹H-NMR spectroscopy or isolated yield. ^aWork-up with 3 N HCl and stirring for a further 3 h. Note that the presented structures are the major isomers. Bn, benzyl; Mes, mesityl; Py, pyridyl; Pym, pyrimidinyl.

Full size image

A series of substituted BCB esters 1 furnished the 1,1,3-trisubstituted cyclobutanes 31–37 (Fig. 3). Thus, BCBs featuring sensitive functional groups, including ester, thiophene, ketone, amide and sulfone (38–41) were efficiently converted to desired products. Furthermore, disubstituted BCBs were identified as amenable substrates (42–47). Here, disubstituted BCBs favoured to form a benzylic radical rather than a tertiary radical, chemo-selectively delivering diarylcyclobutane motifs. Likewise, a wide range of alkyl halides, such as perfluoroalkane halides, fluorine-free alkyl bromide, monofluoroalkyl bromide and difluoroalkyl amides were tolerated to give the desired cyclobutanes 48–57.

Reaction conditions: 1 (0.3 mmol), 2 (3.0 equiv.), 3 (3.0 equiv.), [Ru(O₂CMes)₂(p-cymene)] (10 mol%), P(4-CF₃C₆H₄)₃ (10 mol%), Na₂CO₃ (2.0 equiv.), 1,4-dioxane (2.0 mL), 65 °C, 24–48 h. All yields are isolated yields. The ratios of the diastereomers were determined by ¹H-NMR spectroscopy or isolated yields. Note that the presented structures are the major isomers. In the case of the 1,1,3-trisubstituted cyclobutanes, the cis structure is the major, while for the 1,1,3,3-tetrasubstituted cyclobutanes, the (1r,3r) structure is the major, which was confirmed by X-ray crystallographic analysis (see the X-ray structure of compound 62 in Supplementary Data 6 for details). Naph, 2-naphthyl group.

Full size image

Gram-scale and late-stage derivatization

To demonstrate the practical utility of our BCBs C–C scission/remote activation strategy, cyclobutane 4 was prepared at gram scale with comparable efficacy (Fig. 4a). The site selectivity ensured that pyrimidine, oxazoline and ketimine (vide infra) as well as pyridine and pyrazole were efficiently diversified, extending the viable portfolio (Fig. 4b). Further, a triple activation manifold proved viable in terms of ruthenium(II)-catalysed C−C/meta-C−H and ortho-photo-induced C−H activation (58 and 59).

a, Gram-scale reaction gave the desired product 4 in high yield. b, Various downstream functionalization of products 4, 42 or 46. Cp*, 1,2,3,4,5-pentamethylcyclopentadienyl; DCE, 1,2-dichloroethane; LED, light emitting diode; MMA, methyl methacrylate; Piv, pivaloyl; PMP, p-methoxyphenyl; r.t., room temperature; THF, tetrahydrofuran.

Full size image

DFT calculation and mechanism studies

To gain insights into the reaction mechanism, the site selectivity of radical addition at the two possible BCB sites was probed by means of density functional theory (DFT) calculations (Fig. 5a; see Supplementary Figs. 1, 2, 7 and 8 for details). In the case of monosubstituted BCB 1a, the difluoroalkyl radical preferentially attacked at the unsubstituted carbon, leading to the formation of a more thermodynamically stable tertiary radical. The shorter bridge C−C distance (1.61 Å) and the longer C−C_RF distance (2.21 Å) in TS3-s4, compared with TS4-s2, indicated that the radical attack at the unsubstituted site proceeded through an earlier transition state that structurally resembled the starting BCB 1a. In the case of radical addition to the disubstituted BCB 1m, the ester-substituted site is favoured, resulting in the formation of thermodynamically stable benzylic radical. During the cleavage of the σ-bridge bond in disubstituted BCB 1m, TS7-s1 exhibited an earlier transition state characteristic, evidenced by the slightly elongated C–C bridge distance of BCB 1a (1.63 Å in TS7-s1 and 1.64 Å in TS8-s1) and the relatively larger C–C distances between the BCB 1m and the difluoroalkyl radical (2.25 Å in TS7-s1 and 2.21 Å in TS8-s1). The presynthesized p-cymene-free ruthenacycle 66 yielded the desired product 4 in the presence of MesCO₂H and phosphine ligand (Fig. 5b). The control experiment without a phosphine ligand as well as with alternative ligands, such as bpy or NHC, in the optimization table failed to provide the desired product, highlighting the essential role of the phosphine ligand assistance^76,77,78,79. The key role of the phosphine ligand was further demonstrated by attempting this transformation with carboxylate-free ruthenium(II) phosphine complex 67, yielding the desired product in high yield when MesCO₂H was added (Fig. 5c). The carboxylate-free ruthenium(II) phosphine complex 67 could afford the desired product only in 14% yield even in the absence of MesCO₂H (Fig. 5c). Additionally, radical trapping experiments validated the radical mechanism (see Supplementary Data 7.1.1 for details). On the basis of our mechanism and computational findings, a plausible catalytic cycle is put forwards in Fig. 5d, featuring ruthenacycle A in a ruthenacycle-mediated XAT process to furnish ruthenium(III) intermediate B with an energy barrier of 14.9 kcal mol⁻¹. The thus formed alkyl radical 3^R attacks the BCB 1a at the unsubstituted site to induce strain-release C–C scission with an energy barrier of 15.9 kcal mol⁻¹, forming the tertiary radical C. Species C reacts at the ruthena(III)cycle B para to the C_Ar–Ru bond, delivering the stabilized singlet metallacycle D. Here, the formation of the cis product is favoured over the trans product by 1.4 kcal mol⁻¹. The subsequent rearomatization and proto-demetallation releases the desired cyclobutane 4, thereby regenerating the catalytically active ruthenium(II) species F.

a, Computed relative Gibbs free energies (ΔG_338.15) in kcal mol⁻¹ for radical attack at the monosubstituted BCB 1a and disubstituted BCB 1m were conducted at the B3LYP-D3BJ/def2-TZVP-SMD(1,4-dioxane)//PBE0-D3BJ/def2-SVP level of theory. b, p-Cymene-free ruthenacycle complex 66 as the catalyst. c, Carboxylate-free ruthenium(II) phosphine complex 67 as the catalyst. d, Proposed catalytic cycle associated with relative Gibbs free energies (ΔG_338.15) in kcal mol⁻¹ based on our mechanism studies and DFT calculation. RF, difluoroalkyl; P, P(4-CF₃C₆H₄)₃; L, 1,4-dioxane, 2a and so on.

Full size image

We have achieved the merger of BCBs C–C activation with remote meta-C–H functionalization by a multipotent ruthenium catalyst. The double activation proceeded in a highly chemo- and position-selective fashion and provided access to densely decorated Fsp³-rich cyclobutanes in a single step. Mechanistic studies were suggestive of a Ru-XAT process enabling chemo-selective BCBs opening and meta-diversification.

General methods for 1,3-difunctionalization of BCBs enabled by ruthenium-catalysed remote C–H activation

The general procedure for 1,3-difunctionalization of BCBs was as follows: [Ru(O₂CMes)₂(p-cymene)] (16.8 mg, 10.0 mol%), P(4-CF₃C₆H₄)₃ (14.0 mg, 10.0 mol%), Na₂CO₃ (64 mg, 0.6 mmol, 2.0 equiv.), 1,4-dioxane (2.0 ml), 1 (0.3 mmol, 1.0 equiv.), 2 (0.9 mmol, 3.0 equiv.) and 3 (0.9 mmol, 3.0 equiv.) were added into an oven-dried 20 ml pressure tube. The reaction mixture was stirred at 65 °C for 24–48 h. After cooling to ambient temperature, the mixture was purified by column chromatography on silica gel to afford the corresponding cyclobutanes 4–57.